Medicare Compliance & Reimbursement - 2004 Issue 18
Chemotherapy: Oncologists To CMS: Give Us The Bad News First
Subscribe or sign in to view the full article.
Article Overview
This article discusses chemotherapy-related Medicare payment changes under the Medicare Modernization Act, including the shift in drug pricing methodology and the effect on oncology practice reimbursement. It covers concerns raised by oncologists, professional societies, and lawmakers about CMS payment data, timing, and possible impacts on cancer care. The piece is relevant to oncology practices, coding and billing staff, reimbursement specialists, and anyone tracking Medicare policy changes affecting chemotherapy services.
Why This Topic Matters
The article matters because chemotherapy reimbursement policy can affect practice revenue, payment stability, and access to cancer care. It helps readers understand the broader Medicare payment environment surrounding oncology services and the organizations and lawmakers pushing for earlier disclosure of pricing information.
What You Will Learn
- How Medicare chemotherapy payment policy is changing
- Why oncology practices are concerned about reimbursement uncertainty
- What role CMS and Congress play in setting and reviewing payment information
- How professional societies are responding to chemotherapy payment changes
- Why payment timing and policy updates matter for cancer care delivery
Who Should Read This
- Oncology practices
- Medical coders
- Medical billers
- Reimbursement specialists
- Practice managers
- Healthcare policy readers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com